BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 2nd Quarter - Report

OMNICELL 340B (FKA: PSG LLC)

via WEXFORD SOLUTIONS LLC

2nd Quarter (Apr 1 - June 30) · 2020Posted Jun 30, 2020Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: OMNICELL 340B (FKA: PSG LLC)
Description: Pharmacy automation company
Location: California · United States of America

Registrant

Firm: WEXFORD SOLUTIONS LLC
Description: Lobbying/communications firm
Location: Vienna, Virginia, United States of America

Lobbying activities

1 issue

Health Issues
Discuss importance of 340B drug discount program and policy matters related to the program.
LobbyistsTED SLAFSKY

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

OMNICELL 340B (FKA: PSG LLC) — Lobbying — Receipts Report